Abbott expands with $2.8B purchase deal of LASIK device leader AMO

JANUARY 12, 2009--Abbott (Abbott Park, IL), the global health care and medical research company, announced today a definitive agreement to purchase Advanced Medical Optics (AMO, Santa Ana, CA) for ~$2.8 billion including debt. Globally, AMO holds the number one position in LASIK laser vision correction surgical devices, the number two position in the cataract surgical device market, and the number three position in contact lens care products. The deal gives Abbott a long-term sustainable growth platform with more than $1 billion in annual sales.

"Through superior vision care technologies and service, AMO has established itself as a leader in this multi-billion dollar medical device segment. With AMO, Abbott is enhancing and strengthening its diverse mix of medical device businesses and gaining a leadership position in another large and growing segment," said Abbott chairman and CEO Miles D. White. "Additionally, Abbott's significant global presence will help drive growth opportunities for this business, especially in international markets, where favorable demographics are driving demand for advanced eye care procedures and products."

Jim Mazzo, chairman and CEO of AMO, will remain president of AMO. "Joining forces with Abbott will fortify our position as a global ophthalmic medical device leader and enhance our ability to serve eye care practitioners and patients around the world."

"With AMO, Abbott will immediately become a global leader in vision," said John M. Capek, executive vice president, Medical Devices, Abbott. "The business is poised for long-term growth, driven by advances in refractive surgery technologies, including LASIK, and an aging global population." Population growth and demographic shifts are increasing demand for advanced vision care technologies across all geographies and age groups. For example, about 60 percent of people older than 60 have cataracts, which are the leading cause of vision loss among this age group. It is estimated that 700 million people globally are 60 years or older, and that number is expected to grow to one billion over the next decade.

Under the terms of the agreement, Abbott will commence a tender offer by Jan. 26, 2009, to purchase all outstanding shares of AMO at $22 per share. The tender offer is conditioned on the tender of a majority of the outstanding shares of AMO's common stock on a fully diluted basis. The $2.8 billion estimated value of the transaction is based on AMO's approximately 62 million fully diluted shares outstanding, plus estimated net debt at the time of closing. The Boards of Directors of AMO and Abbott have approved the transaction. Abbott expects the transaction to be neutral to ongoing earnings per share in 2009, and accretive beginning in 2010, both before one-time transaction-related costs, which will be provided at a later date.

The transaction is subject to customary closing conditions, including antitrust clearances. Abbott and AMO expect the transaction to close in the first quarter of 2009.

More information:
News releases and other information on Abbott's Web site
Advanced Medical Optics
Report on recent LASIK market
Bausch & Lomb's recent laser eye surgery deal

Posted by Barbara G. Goode, barbarag@pennwell.com.

Get All the BioOptics World News Delivered to Your Inbox

Subscribe to BioOptics World Magazine or email newsletter today at no cost and receive the latest news and information.

 Subscribe Now
Related Articles

(SLIDESHOW) View the July/August 2013 issue

Sales of Coherent lasers for ophthalmology exceed 10,000 units

Coherent has now shipped over 10,000 lasers into ophthalmic applications, including pulsed excimer ultraviolet lasers for LASIK vision correction and continuous-wave (CW) solid-state lasers with gr...

WaveTec Vision secures $16.5M to market cataract surgery system

WaveTec Vision has closed a new round of financing for its recently introduced ORA System, a wavefront aberrometry system for cataract surgery, securing an additional $16.5 million.

Anterior segment module receives FDA clearance

Heidelberg Engineering has gained FDA clearance for its Spectralis anterior segment module, which provides high-resolution images of the cornea, anterior chamber angle, and sclera using the company...

BLOGS

Neuro15 exhibitors meet exacting demands: Part 2

Increasingly, neuroscientists are working with researchers in disciplines such as chemistry and p...

Why be free?

A successful career contributed to keeping OpticalRayTracer—an optical design software program—fr...

LASER Munich 2015 is bio-bent

LASER World of Photonics 2015 included the European Conferences on Biomedical Optics among its si...

White Papers

Understanding Optical Filters

Optical filters can be used to attenuate or enhance an image, transmit or reflect specific wavele...

How can I find the right digital camera for my microscopy application?

Nowadays, image processing is found in a wide range of optical microscopy applications. Examples ...

CONNECT WITH US

            

Twitter- BioOptics World

Copyright © 2007-2016. PennWell Corporation, Tulsa, OK. All Rights Reserved.PRIVACY POLICY | TERMS AND CONDITIONS